What Vitamin D3 and K2 Do Alone and Together

Vitamin D3 and K2 have separate evidence, and the strongest data belong to vitamin D on its own. In the Vitamin D and Omega-3 Trial, which enrolled 25,871 midlife and older adults not selected for deficiency, vitamin D3 did not lower cancer, cardiovascular events or fractures.^2,3 Vitamin K2 is a cofactor for proteins involved in inhibiting arterial calcification, and a three-year K2 bone trial enrolled postmenopausal women.^6,8 Combination trials are few and mixed.^7,8 Your age, history and any bone or medication issues decide whether either belongs in your plan.

Vitamin D3 on Its Own

Vitamin D has long been recognized for its role in calcium balance and skeletal health.⁵ Vitamin D3, or cholecalciferol, is the form the Vitamin D and Omega-3 Trial tested.² The question for you is whether taking it adds anything when you are not deficient.

Endocrine Society Guidance on Who Benefits

The Endocrine Society's 2024 guideline sets out who it suggests should take vitamin D without first testing. It suggests empiric vitamin D for children and teens aged 1 to 18, for adults aged 75 and older, for people who are pregnant, and for people with high-risk prediabetes.¹ For adults aged 75 and older, the stated reason was the potential to lower the risk of death.¹

For healthy adults younger than 75, the panel suggests against vitamin D above the current Dietary Reference Intakes (DRI) to lower disease risk.¹ It also suggests against routine testing of 25-hydroxyvitamin D (25(OH)D), the blood marker of vitamin D status, in the populations it considered.¹

Those suggestions do not apply to people with an established reason for vitamin D treatment or testing.¹ If you have a bone condition or another documented indication, your physician works from that indication. The osteoporosis in men page covers how bone loss is evaluated. For vitamin D and cognition, see vitamin D and memory, and for the wider supplement picture, see best supplements for men.

The Vitamin D and Omega-3 Trial in Adults Without Deficiency

The Vitamin D and Omega-3 Trial randomized 25,871 men aged 50 or older and women aged 55 or older in the United States. Participants took vitamin D3 at 2000 IU per day or placebo, a trial dose and not a recommendation for you.² The same trial also tested fish oil, covered in omega-3 for men.

Over a median of 5.3 years, vitamin D did not lower the risk of invasive cancer or major cardiovascular events.² The trial found no excess risk of high blood calcium or other adverse events.² A fracture analysis of the same trial found that vitamin D3 did not lower total, nonvertebral or hip fractures.³ Participants were not chosen for vitamin D deficiency, low bone mass or osteoporosis.³

If you are a generally healthy man in midlife without a deficiency or bone problem, extra vitamin D3 is unlikely to prevent cancer, heart events or fractures. If you do have a deficiency or a bone diagnosis, these trials do not answer your question, and your physician should.

Vitamin D and Testosterone

Randomized trials have not shown vitamin D raising testosterone in men. A 2017 trial randomized healthy men to vitamin D3 or placebo for 12 weeks, and 98 completed it. The men had normal testosterone and vitamin D levels below 75 nmol/L at the start.⁴ Vitamin D had no effect on total testosterone.⁴ It did lower an index of insulin sensitivity, a reason to review metabolic labs with your physician.⁴

A 2026 meta-analysis pooled 11 comparisons and found no clear effect of vitamin D on total testosterone, sex hormone-binding globulin (SHBG) or free androgen index.⁵ The certainty of evidence was low.⁵ If your goal is testosterone, your testosterone result and symptoms are where your physician starts. For other supplements studied for testosterone, see testosterone supplements.

Vitamin K2 on Its Own

Menaquinone-7 (MK-7), a form of vitamin K2, is a cofactor for the carboxylation of proteins involved in inhibiting arterial calcification.⁸ Carboxylation is a chemical step that switches those proteins on. In a three-year K2 bone trial, the ratio of undercarboxylated to carboxylated osteocalcin, a bone protein, served as the marker of vitamin K status.⁶

That trial ran three years in 244 healthy postmenopausal women. MK-7 improved vitamin K status and slowed the age-related decline in bone density at the lumbar spine and femoral neck, but not at the total hip.⁶ The authors wrote that whether these results extend to men needs further investigation.⁶

For you as a man, that means K2 has a plausible role and limited direct evidence. It is worth raising with your physician if bone health is part of your picture.

The D3 and K2 Combination

Evidence for the pair taken together is thin and mixed. A 2020 meta-analysis pooled 8 randomized trials with 971 participants and found that vitamin K combined with vitamin D increased total bone mineral density.⁷ The combination also lowered undercarboxylated osteocalcin.⁷ The same paper noted that earlier studies had not reached a consistent conclusion on bone quality.⁷ It measured bone density, which is a marker, and did not report fractures.

AVADEC, a combination trial in men, looked at the heart valve. It randomized 365 men with a mean age of 71 and existing aortic valve calcification to MK-7 plus vitamin D or placebo for two years.⁸ The combination did not slow calcification of the aortic valve, and aortic and coronary artery calcification scores did not differ from placebo.⁸

If you take vitamin D3 and K2 together, the bone density signal is the best-supported reason. The heart-calcification claim did not hold up in the trial that tested it in older men. If artery or valve calcification is your concern, your physician works from your cardiovascular history and labs instead.

Vitamin D3, K2 and the Combination Compared

Vitamin D earns its place when you have a reason for it, and K2 adds a modest bone case on top. Your physician weighs both against your age, bone history and medications.

Vitamin K and Warfarin

Vitamin K directly opposes warfarin, a blood thinner. The Jantoven (warfarin) label describes the drug as a vitamin K antagonist with a narrow therapeutic range whose action may be affected by dietary vitamin K.⁹ The label lists increased vitamin K intake as a factor that can lower the INR response, the blood test used to monitor warfarin.⁹

The label advises patients to keep a consistent amount of vitamin K in their diet. It also calls for more frequent INR monitoring when starting or stopping other products, including botanicals.⁹ If you take warfarin, talk to the clinician managing it before you start or stop a K2 product, so your INR can be checked.

The Opt Take on Vitamin D3 and K2

A D3 and K2 supplement is the same capsule for every man who buys it. Your reasons for taking it are not the same, and the evidence only supports it for some of them. A plan built from your numbers and history gets that match right.

At Opt Health, your initial panel covers 55+ biomarkers spanning hormones, inflammation, cardiovascular risk and more, taken at home or at a partner lab. A physician reviews your results with you 1:1 and checks your existing conditions and current medications, including anything like warfarin. Your plan can include prescriptions, peptides and supplements shipped from our pharmacy to your home.

Full labs and a physician consultation repeat every 3 to 4 months. Your physician compares the new results with your baseline and adjusts the plan, adding, keeping or dropping a supplement based on what your numbers did.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.